CN109476743A - 预防或缓解毒性的早期干预方法 - Google Patents

预防或缓解毒性的早期干预方法 Download PDF

Info

Publication number
CN109476743A
CN109476743A CN201780031706.6A CN201780031706A CN109476743A CN 109476743 A CN109476743 A CN 109476743A CN 201780031706 A CN201780031706 A CN 201780031706A CN 109476743 A CN109476743 A CN 109476743A
Authority
CN
China
Prior art keywords
therapy
cell
substance
processing
given
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780031706.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·詹森
R·加德纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58609964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109476743(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of CN109476743A publication Critical patent/CN109476743A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201780031706.6A 2016-03-22 2017-03-22 预防或缓解毒性的早期干预方法 Pending CN109476743A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662311906P 2016-03-22 2016-03-22
US62/311,906 2016-03-22
US201662417287P 2016-11-03 2016-11-03
US62/417,287 2016-11-03
US201662429722P 2016-12-02 2016-12-02
US62/429,722 2016-12-02
PCT/US2017/023676 WO2017165571A1 (en) 2016-03-22 2017-03-22 Early intervention methods to prevent or ameliorate toxicity

Publications (1)

Publication Number Publication Date
CN109476743A true CN109476743A (zh) 2019-03-15

Family

ID=58609964

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780031706.6A Pending CN109476743A (zh) 2016-03-22 2017-03-22 预防或缓解毒性的早期干预方法

Country Status (13)

Country Link
US (5) US11518814B2 (https=)
EP (3) EP4545143A3 (https=)
JP (3) JP7048571B2 (https=)
KR (1) KR20190021200A (https=)
CN (1) CN109476743A (https=)
AU (2) AU2017238218B2 (https=)
BR (1) BR112018069251A2 (https=)
CA (1) CA3018588A1 (https=)
ES (1) ES2907557T3 (https=)
MA (2) MA44486A (https=)
MX (1) MX2018011480A (https=)
RU (1) RU2018136877A (https=)
WO (1) WO2017165571A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
MX392487B (es) 2014-10-20 2025-03-21 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva.
US11815514B2 (en) 2015-12-04 2023-11-14 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
MX2018011480A (es) * 2016-03-22 2019-03-28 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Metodos de intervencion temprana para prevenir o aminorar toxicidad.
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
BR112019011065A2 (pt) * 2016-12-03 2019-10-01 Juno Therapeutics Inc métodos para determinação da dosagem de células t car
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
BR112019017767A2 (pt) 2017-02-27 2020-04-07 Juno Therapeutics Inc composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
MA51210A (fr) * 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
KR102925957B1 (ko) 2018-02-16 2026-02-11 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
EP3762012A1 (en) * 2018-03-09 2021-01-13 Ospedale San Raffaele S.r.l. Il-1 antagonist and toxicity induced by cell therapy
JP2021523090A (ja) * 2018-03-09 2021-09-02 科済生物医薬（上海）有限公司Ｃａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．，Ｌｔｄ． 腫瘍を治療するための方法および組成物
WO2019195823A1 (en) * 2018-04-06 2019-10-10 The Board Of Regents Of The University Of Texas System Prediction and treatment of immunotherapeutic toxicity
WO2021028469A1 (en) * 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
EP4013420B1 (en) * 2019-08-14 2023-11-01 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院（Dba西雅图儿童研究所） 抗二硝基苯酚的嵌合抗原受体
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
US20230366893A1 (en) * 2020-09-29 2023-11-16 Washington University Methods to determine risk of neurotoxicity
CA3204374A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
UA129643C2 (uk) 2021-05-03 2025-06-18 Інсайт Корпорейшн Інгібітори шляху jak1 для лікування вузлуватого свербця

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249742A (zh) * 2010-09-16 2013-08-14 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体
WO2014011984A1 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Toxicity management for anti-tumor activity of cars
WO2016132366A1 (en) * 2015-02-18 2016-08-25 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
WO2017035362A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US265209A (en) 1882-09-26 Automatic feeder for perforators
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
WO1994009138A1 (en) 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP2032167B1 (en) * 2006-06-22 2016-08-17 CellAct Pharma GmbH A novel target in the treatment of cytokine release syndrome
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
MX2018011480A (es) * 2016-03-22 2019-03-28 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Metodos de intervencion temprana para prevenir o aminorar toxicidad.
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249742A (zh) * 2010-09-16 2013-08-14 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体
WO2014011984A1 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Toxicity management for anti-tumor activity of cars
CN104427997A (zh) * 2012-07-13 2015-03-18 宾夕法尼亚大学董事会 对cars的抗肿瘤活性的毒性管理
WO2016132366A1 (en) * 2015-02-18 2016-08-25 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
WO2017035362A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DANIEL W. LEE ET AL.: ""Current concepts in the diagnosis and management of cytokine release syndrome"", 《BLOOD》 *
DAVID T. TEACHEY ET AL.: ""Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy"", 《BLOOD》 *
JAINA M. PATEL ET AL.: ""Cancer CARtography: Charting out a new approach to cancer immunotherapy"", 《IMMUNOTHERAPY》 *
MARCO L DAVILA ET AL.: ""CD19-targeted T Cells for Hematologic Malignancies: Clinical Experience to Date"", 《CANCER J》 *
MARCO L. DAVILA ET AL.: ""Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia"", 《SCI TRANSL MED》 *
SETH J. ROTZ ET AL.: ""Severe cytokine release syndrome in a patient receiving PD-1-directed therapy"", 《PEDIATRIC BLOOD ＆ CANCER》 *
SHANNON L. MAUDE ET AL.: ""Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia"", 《N ENGL J MED》 *
SHANNON L. MAUDE ET AL.: ""Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies"", 《CANCER J》 *
STEPHAN A. GRUPP ET AL.: ""Advances in T-cell therapy for ALL"", 《BEST PRACTICE & RESEARCH CLINICAL》 *
STEPHAN A. GRUPP ET AL.: ""Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia"", 《N ENGL J MED》 *
SUJIN KANG ET AL.: ""Therapeutic uses of anti-interleukin-6 receptor antibody"", 《INTERNATIONAL IMMUNOLOGY》 *
TOSHIO TANAKA ET AL.: ""Immunotherapeutic implications of IL-6 blockade for cytokine storm"", 《IMMUNOTHERAPY》 *
钱军 等: ""细胞因子释放综合征的发生机制和防治策略"", 《肿瘤研究与临床》 *

Also Published As

Publication number Publication date
ES2907557T3 (es) 2022-04-25
US11518814B2 (en) 2022-12-06
US20190112379A1 (en) 2019-04-18
WO2017165571A1 (en) 2017-09-28
JP2019509351A (ja) 2019-04-04
MA44486A (fr) 2019-01-30
US20240425608A1 (en) 2024-12-26
MA71266A (fr) 2025-04-30
MX2018011480A (es) 2019-03-28
CA3018588A1 (en) 2017-09-28
RU2018136877A (ru) 2020-04-22
EP4545143A3 (en) 2025-07-23
JP7048571B2 (ja) 2022-04-05
EP4015536A1 (en) 2022-06-22
BR112018069251A2 (pt) 2019-01-22
KR20190021200A (ko) 2019-03-05
US20230322937A1 (en) 2023-10-12
US20230212298A1 (en) 2023-07-06
JP2024156736A (ja) 2024-11-06
EP4545143A2 (en) 2025-04-30
US11760804B2 (en) 2023-09-19
AU2017238218B2 (en) 2024-05-02
AU2017238218A1 (en) 2018-10-11
JP2022088489A (ja) 2022-06-14
EP3433276A1 (en) 2019-01-30
AU2024205049A1 (en) 2024-08-15
EP3433276B1 (en) 2021-12-22
US20230091447A1 (en) 2023-03-23
JP7528143B2 (ja) 2024-08-05
US12098208B2 (en) 2024-09-24

Similar Documents

Publication Publication Date Title
CN109476743A (zh) 预防或缓解毒性的早期干预方法
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
JP7134204B2 (ja) キメラ受容体及びその使用方法
TWI851650B (zh) Ｇｐｒｃ５ｄ嵌合抗原受體及表現其之細胞
JP7575104B2 (ja) ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖
Romee et al. Utilizing cytokines to function‐enable human NK cells for the immunotherapy of cancer
Turka et al. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes.
JP2022513778A (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
CN111386125A (zh) 多肽
JP2021525518A (ja) 細胞をゲノム編集及び活性化するための方法
JP2024527559A5 (https=)
CN119998322A (zh) 基因编辑靶基因以增强自然杀伤细胞功能
JP2006528627A (ja) アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物
US20250304913A1 (en) Chimeric antigen receptor t cells and methods of use thereof
US20250268941A1 (en) Bcma/cd19 car for treating multiple myeloma
HK40126667A (zh) 嵌合抗原和t细胞受体及使用的方法
HK40128442A (zh) 嵌合抗原和t细胞受体及使用的方法
CN120917054A (zh) 嵌合细胞因子受体，其包含截短的IL2Rβ和IL2Rγ
CN119790063A (zh) 免疫细胞疗法
HK40074994A (en) Early intervention methods to prevent or ameliorate toxicity
CN109562127A (zh) 作为早期治疗选择的过继细胞疗法
EA051270B1 (ru) Химерные рецепторы и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination